Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,680 recruiting studies in this area right now.
By phase
- Not applicable9,832
- Phase 24,469
- Phase 12,739
- Phase 1/Phase 21,689
- Phase 31,406
- Phase 2/Phase 3282
- Phase 4263
Top conditions
- Breast Cancer1,231
- Cancer658
- Prostate Cancer658
- Colorectal Cancer494
- Lung Cancer429
- Ovarian Cancer338
- Multiple Myeloma330
- Gastric Cancer300
- Pancreatic Cancer297
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma285
- Solid Tumor258
- Advanced Solid Tumor255
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer205
- Advanced Solid Tumors195
- Esophageal Cancer195
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University311
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- National Cancer Institute (NCI)288
- Mayo Clinic236
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto126
Where studies are running
- California1,425
- Texas640
- Arizona512
- Florida443
- Alabama421
- New York412
- Massachusetts339
- Maryland328
- New Jersey268
- Pennsylvania241
Recruiting studies20,680 total
- NCT05664464RecruitingPhase 1/Phase 2
Glutamate drugs for newly diagnosed brain tumor treatment
This Phase 1/2 study tests whether “glutamate inhibitor” medications can be safely added for newly diagnosed glioblastoma, and how they affect treatment outcomes. It’s designed for adults who will also receive the standard chemo‑radiation plan with temozolomide.
Zurich, Canton of ZurichAges 18 years+ - NCT05664867Recruiting
Program study for hereditary breast or colon cancer counseling in clinics
This study helps clinics roll out cancer genetic counseling services for people who may have inherited cancer risk. If you may need genetic testing for hereditary breast or colon cancer, you can be interviewed about your experience with these services.
Chicago, IllinoisAges 25 years+ - NCT05665361RecruitingPhase 1/Phase 2
Testing palbociclib plus sasanlimab for advanced kidney cancers
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Bethesda, MarylandAges 18–100 - NCT05665504Recruiting
Biomarker test for managing early lung nodules after treatment
This study looks at lung “biomarkers” (test results from your nodule/tissue) to better predict risk of cancer coming back and to guide long-term follow-up. It may help doctors choose the best surveillance plan after surgery or other treatment for early, potentially curable lung cancer.
Tampa, FloridaAges 18 years+ - NCT05665920Recruiting
Shorter radiation after breast surgery for certain node-positive cancer
This trial compares a shorter, more concentrated radiation schedule versus a standard shorter schedule after breast-conserving surgery. It looks at whether the treatment works well and is safe, especially for women whose lymph nodes also need radiation.
São Paulo, São PauloAges 18 years+ - NCT05667532Recruiting
Contrast mammogram screening for women with dense breasts
This study tests how well a special mammogram with contrast can help assess breast cancer risk in women with dense breast tissue. It may help improve screening planning, especially when standard mammograms are harder to read due to density.
Houston, TexasAges 30–75 - NCT05667506RecruitingPhase 1/Phase 2
Check CNCT19 cell therapy for relapsed childhood ALL
This early-stage trial tests a personalized immune-cell treatment called CNCT19 in children and teens whose leukemia (ALL) has come back or not responded to prior therapy. It may help the immune system recognize and attack leukemia cells that carry CD19.
Hefei, AnhuiAges 3–18 - NCT05667948Recruiting
Testing targeted treatments for thymus cancer using tumor testing
This trial studies people with thymus (thymic) cancers that have been confirmed by tissue testing. It uses tumor “molecular” (biologic/genetic) test results to guide treatment options and see how well they work.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Washington D.C., District of ColumbiaAges 12 years+ - NCT05669339RecruitingPhase 2
AI-guided dosing study for advanced liver cancer patients
This Phase 2 study tests whether an artificial intelligence tool can help doctors choose the right dose for treating advanced hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve safety and effectiveness by matching treatment to you using your liver function, lab results, and treatment course.
Gainesville, FloridaAges 18–99 - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Los Angeles, CaliforniaAges 18 years+ - NCT05669820RecruitingPhase 2/Phase 3
Study drug for aggressive brain tumor after surgery
This trial tests an “antisecretory factor” treatment in people with grade 4 glioblastoma (or astrocytoma). It aims to see whether it can improve outcomes when used alongside planned cancer treatments after surgery.
LundAges 18–75 - NCT05669846RecruitingPhase 2
FMT plus pembrolizumab for advanced lung cancer after prior treatment
This Phase 2 trial studies whether adding fecal microbiome transplant (FMT) to pembrolizumab can help people with advanced, PD-L1–positive non-small cell lung cancer that has returned or progressed after anti–PD-1/PD-L1 therapy. You may be asked to give new tumor tissue and undergo gut procedures, because the study aims to change gut bacteria to boost the immune response.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05670938Recruiting
Follow-up after testicular cancer surgery and chemotherapy
This study looks at how people should be followed after treatment for testicular cancer (surgery and, for some, chemotherapy). It may help improve follow-up plans while keeping an eye out for cancer coming back.
Rotterdam, South HollandAges 18 years+ - NCT05671887Recruiting
Double lung transplant registry for certain lung-limited cancers
This study follows people who are getting a double lung transplant and have specific lung-only (or lung-limited) cancer or other serious lung conditions. It’s an observational registry, meaning it collects real-world information to learn which patients may benefit from transplant and how they do afterward.
Chicago, IllinoisAges 18–75 - NCT05671458Recruiting
Imaging guidance during head and neck tumor surgery plus radiation
This trial tests whether advanced imaging used during surgery can better guide where surgeons remove head-and-neck tumors. It also studies how this approach works alongside planned postoperative radiation therapy, which may be needed for more advanced tumors.
HeidelbergAges 18 years+ - NCT05672043Recruiting
Study genetic risks in children with malignant brain tumors
This study looks at genetic (DNA/molecular) features of malignant brain tumors in children. It may help doctors better understand tumor risk patterns and guide future treatment planning.
Beijing, Beijing MunicipalityAges birth–18 years - NCT05672485Recruiting
Scan prostate cancer using a radioactive tracer SPECT/CT
This trial uses a special imaging scan (SPECT/CT) with a small amount of radioactive tracer to look at prostate cancer. It aims to see how well the scan matches your prostate cancer tests and may help improve detection and assessment.
Xi'an, ShaanxiAges 18 years+ - NCT05672108RecruitingPhase 2
Chemo delivered into lung tumors using a catheter
This trial studies a treatment that delivers chemotherapy directly to lung tumors by placing a catheter into lung blood vessels. It may help people with lung cancer or lung metastases that are growing despite standard treatment, or who cannot tolerate it.
Duarte, CaliforniaAges 18 years+ - NCT05672147RecruitingPhase 1
CD33 CAR T cells for hard-to-treat AML
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
Duarte, CaliforniaAges 18 years+ - NCT05672524RecruitingPhase 2
Tucatinib plus trastuzumab for HER2-positive rectal cancer
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Basking Ridge, New JerseyAges 18 years+ - NCT05672615Recruiting
Mood changes during bladder cancer treatment with BCG
This study looks at how bladder cancer treatment with BCG may affect mood and emotional well-being. It may help doctors understand which patients experience mood changes during care.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05673031Recruiting
PET/CT scan test for neuroendocrine tumors with a special tracer
This study uses a PET/CT scan with a small amount of radioactive tracer to see how neuroendocrine tumors are behaving in adults. It may help doctors better detect and evaluate these tumors, especially when symptoms suggest a carcinoid-type hormone problem.
Calgary, AlbertaAges 18–100 - NCT05673304Recruiting
Boost treatment before surgery for luminal B breast cancer
This trial tests a “boost” treatment given before surgery along with standard chemotherapy for luminal B–type breast cancer. It may help improve outcomes by strengthening treatment before the tumor is removed.
BolognaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,680 recruiting oncology studies from the U.S. registry right now, out of 31,878 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.